Company Overview
DBV Technologies
DBVT is a clinical-stage biotech developing epicutaneous immunotherapy (EPIT) via the Viaskin® patch for food allergies—an easy, non-invasive approach for pediatrics.
Key Catalysts
Phase 3 Win (VITESSE): VIASKIN Peanut achieved 46.6% response vs. 14.8% placebo in children 4–7, validating efficacy and safety ahead of a planned BLA in H1 2026.
Regulatory & Funding Momentum: Warrant exercises bolster cash; plans to expand into younger age groups increase addressable market.
Durability & Platform Potential: Long-term extension data support sustained benefit and optionality across multiple food allergies.
Why It Matters
Non-invasive, patch-based therapy = high caregiver/child acceptance
Clear regulatory path plus broader age expansion → larger, earlier TAM
Platform line-of-sight beyond peanut to multi-allergen pipeline
Investment Outlook
Bullish above: $14.50–$15.00
Target: $28–$30 — supported by Phase 3 efficacy, upcoming BLA, and platform durability.
#DBVT #Viaskin #EPIT #FoodAllergy #Pediatrics #Biotech
DBV Technologies
DBVT is a clinical-stage biotech developing epicutaneous immunotherapy (EPIT) via the Viaskin® patch for food allergies—an easy, non-invasive approach for pediatrics.Key Catalysts
Phase 3 Win (VITESSE): VIASKIN Peanut achieved 46.6% response vs. 14.8% placebo in children 4–7, validating efficacy and safety ahead of a planned BLA in H1 2026.
Regulatory & Funding Momentum: Warrant exercises bolster cash; plans to expand into younger age groups increase addressable market.
Durability & Platform Potential: Long-term extension data support sustained benefit and optionality across multiple food allergies.
Why It Matters
Non-invasive, patch-based therapy = high caregiver/child acceptance
Clear regulatory path plus broader age expansion → larger, earlier TAM
Platform line-of-sight beyond peanut to multi-allergen pipeline
Investment Outlook
Bullish above: $14.50–$15.00
Target: $28–$30 — supported by Phase 3 efficacy, upcoming BLA, and platform durability.
#DBVT #Viaskin #EPIT #FoodAllergy #Pediatrics #Biotech
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。